RxDoctor Payments Data

Sharon Bradni, NP

Critical Care Medicine · Fresno, CANPI 1902314933

Payments from drug & device makers

$9,765in general payments, 2019–2025

Across 201 payments — averaging $48.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • AbbVie$1K
  • UCB, Inc.$629
  • Amgen$369
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$1,00710%
  • Food & beverage$8,53787%
  • Education$2212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,765 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$35,624
Medicare patients
203
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Carbidopa-LevodopaCarbidopa/Levodopa106$4,942
Memantine Hcl47$2,272
AmantadineAmantadine Hcl50$1,960
Levetiracetam24$1,672
Gabapentin54$1,073
Oxcarbazepine13$1,053
Donepezil Hcl68$806
Primidone16$592
Topiramate12$299
Pregabalin19$250
Duloxetine Hcl17$144
Escitalopram Oxalate14$94
Naproxen11$43

Paid to pharmacies, not to this prescriber.

Other critical care medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →